Sign In
Last checked at 
20 Feb 2018 07:00
For immediate release | 20 February 2018 |
Β
Β
Β
Β
Β
Futura Medical plc
("Futura" or "the Company")
Β
Directorate Changes
Β
Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, announces that Derek Martin, the Company's Finance Director, has resigned from the Board and will leave the Company with effect from the date of this announcement to pursue other business interests.
Β
Angela Hildreth will join the Company in the role of Finance Director, Chief Operating Officer and Board Director with effect from the date of this announcement. Angela is an experienced executive with a track record gained in financial, operational and strategic roles in healthcare and other industries. Angela's experience includes the AIM market and development-stage companies.
Β
Angela was most recently the UK finance director of Shield Therapeutics plc, having joined the business as its financial controller in 2011 when it was an unquoted start-up. Her breadth of roles at the business included finance, business development, human resources and IT.
Β
James Barder, Futura's Chief Executive, said: "On behalf of the Board, I would like to thank Derek for his contribution to the development of the Company during almost 10 years as Finance Director having been appointed on 24 September 2008. We wish him all the best in his future activities.
Β
"I am delighted to welcome Angela to the role of FD and COO at Futura. Her breadth of knowledge and commercial experience in the pharmaceutical sector will be of great value to the Company at a key stage in our development."
Β
Β
The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies. Angela Hildreth (nΓ©e Bowman), aged 38 years, has been a director of the following companies during the five years preceding the date of this announcement:
Β
Current directorships Past directorships
Quaff Box Limited Shield Therapeutics Switzerland AG
Shield TX UK Limited
Phosphate Therapeutics Limited
Β
There is no further information to be disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.
Β
Β
For any further information please contact:
Β
Β
Futura Medical plc | Β |
James Barder, Chief Executive Β | Tel: +44 (0)1483 685 670 |
mail to: james.barder@futuramedical.com | www.futuramedical.com |
Β Β | Β |
N+1 Singer (Nominated Adviser and Broker) | Β |
Aubrey Powell / Liz Yong Β | Tel:+44 (0) 20 7496 3000 |
Β | Β |
For media enquiries please contact: Β | Β |
Buchanan | Β |
Mark Court / Sophie Wills / Stephanie Watson | Tel: +44 (0)20 7466 5000 |
Β
Β
Β
Notes to Editors
Β
Futura Medical plc
Β
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Β
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.
Β
www.futuramedical.com
Β
Follow the stocks
